Sweden’s Xbrane Lays Out Ranibizumab Ambitions
As Key Biosimilar Trial Affected By COVID-19
Executive Summary
Through a partnership with Stada, Sweden’s Xbrane is looking to introduce a biosimilar to Lucentis in major developed markets, including the EU and the US, where the hunt for a commercialization partner continues.
You may also be interested in...
Xbrane’s Ranibizumab Marches On With US FDA Filing Imminent
With Samsung Bioepis already holding US and EU approvals for biosimilar ranibizumab, Swedish sponsor Xbrane Biopharma says 12-month Phase III data supports ongoing registration of the Lucentis rival in both regions.
Xbrane Expands Capacity To Target More Biosimilars
Sweden’s Xbrane Biopharma is moving to new premises that will expand its development capacity and allow it to target several blockbuster biologics with patents expiring over the next decade.
Xbrane And Stada’s Ranibizumab Snapped Up In North America
Bausch + Lomb has struck a deal for US and Canadian rights to the Xlucane ranibizumab biosimilar rival to Lucentis that is being developed by Xbrane Biopharma and Stada.